Start here if you're new
what it is
Apogee is trying to make antibody drugs for eczema, asthma, and COPD.
how it gets paid
Product revenue is effectively $0—pre-revenue biotech. Do not label 50% of sales on a pipeline asset; use R&D focus or program priority instead.
what just happened
Apogee posted -$3.19 EPS, and product revenue was not meaningful in this print.
At a glance
B+ balance sheet — decent shape, but not bulletproof
-$3.30 fy2024 eps est
1.5 beta
~$5B market cap
mid cap
xvary composite: 58/100 — below average
What they do
Apogee is trying to make antibody drugs for eczema, asthma, and COPD.
APG777 and APG808 give you two shots at the same immune problem. One program is not a moat, but two lead assets are better than one. With 196 employees, you are backing a small team, not a giant sales force.
How they make money
~$0
product revenue · clinical-stage—bars show R&D / management attention mix, not sales dollars
APG777 / atopic dermatitis
priority
lead
APG808 / COPD
priority
follow-on
Other I&I programs
priority
early
The products that matter
lead clinical asset
apg777
2026 initial data readout
It is the lead asset behind a company valued at roughly $5B. The first major readout is expected in 2026, which tells you exactly where the market's attention sits.
lead program
follow-on program
apg808
2 named assets shown
This is one of only two named assets in the snapshot. That is the quiet part loud: your upside and your execution risk sit in a very small set of programs.
second shot
valuation lens
clinical pipeline
5.6x book value
At 5.6x book, you are paying for what the pipeline might become, not what the balance sheet is worth today. The catch: there is no approved-product revenue here to cushion a disappointment.
expect volatility
Key numbers
$70.91
share price
This is what one share costs right now, so every percent move matters.
$5B
market cap
The market is paying $5B for a company still trying to prove its drugs work.
1.5
beta
A beta of 1.5 means the stock has moved about 50% more than the market.
$6M
long-term debt
This is tiny next to a $5B market cap, so debt is not the big problem here.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
- long-term debt $6M (0% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for APGE right now.
source: institutional data · return history unavailable
What just happened
verify period vs est.
Apogee posted -$3.19 EPS, and product revenue was not meaningful.
The strip shows ~-$3.30 FY2024 EPS est. If -$3.19 is the same FY window, it is a slightly narrower loss than that est.; if -$3.19 is a quarter, do not compare it to the FY est. without the filing. Pre-revenue biotech: losses matter more than sales.
-$3.19
eps
~$0
product rev
—
margin n/a
the number that mattered
-$3.19 EPS shows the company is still paying for trials—there is no product revenue cushion yet.
source: EDGAR filing
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
Apogee's risk stack is not generic biotech wallpaper. It is APG777 data risk first, then the consequences of being valued at ~$5B before that proof arrives.
med
APG777 disappoints or slips past 2026
The lead program is carrying most of the valuation burden. If the readout weakens confidence, or the timeline moves out, the market loses its main reason for paying 5.6x book today.
Impact: a weaker or later readout leaves investors defending a ~$5B market cap with less proof and more patience.
med
You do not have many shots on goal here
Only two named assets appear in this snapshot: APG777 and APG808. That is not pipeline breadth. That is concentration wearing a lab coat.
Impact: if one program stumbles, the other one has to carry far more of the story than investors probably wanted.
med
The stock already trades like a repricing machine
Price stability is 5 / 100, and the 52-week range runs from $26 to $85. The business may not have product revenue yet, but the stock definitely has mood swings.
Impact: even routine timing language can produce outsized moves when the market is this sensitive to the clinical calendar.
If the pipeline slips, you own a $5B story with no sales to cushion it.
source: institutional data · regulatory filings · risk analysis
Pay attention to
lead catalyst
APG777 initial data readout
Expected in 2026. This is the event that either justifies a ~$5B valuation or makes 5.6x book look very ambitious.
next update
early June 2026 company update
You want the wording on cash use, program sequencing, and timing. In milestone-driven biotech, language moves first and numbers move later.
ownership signal
March 2026 insider sale context
The CEO sold 20,000 shares under a 10b5-1 plan. That is not a clean bearish tell. It is a reminder to watch whether future insider activity stays routine or starts to broaden.
sentiment gauge
price stability staying at 5 / 100
This score tells you the market already treats APGE like a catalyst vehicle. If volatility climbs into 2026, expectations are probably getting even louder.
Analyst rankings
balance sheet grade
B+
solid financial footing, but not the kind of sheet that makes execution risk disappear
risk rank
2 top 40%
in human-speak: the balance-sheet risk profile looks better than most stocks on this specific measure
price stability
5 / 100 very low
when the market re-prices the story, it tends to do it all at once
street coverage
thin
there is not enough here to turn consensus into a useful shortcut. you need to follow the data calendar instead
source: institutional data
Institutional activity
institutional ownership data for APGE is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$71
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive